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Introduction
Breast cancer is one of the most common causes of death, worldwide. The increasing incidence of breast cancer and its associated mortality highlight the need for new therapeutic development, especially targeted treatment (1) .
The course of breast cancer is influenced by several prognostic parameters, including histological type and grade, tumor size, proliferation index, lymph node status, lymphatic and vascular invasion, Estrogen (ER) and Progesterone (PR) receptor status etc. (2) .
Amplification of HER2 gene is associated with rapid progression of the disease, increased metastatic potential and resistance to tamoxifen. The discovery of targeted therapy against the HER2 gene Vol. 12 No.1 Winter 2017 IRANIAN JOURNAL OF PATHOLOGY (Herceptin) has brought an effective treatment modality for breast cancer patients (3) .
Immunohistochemistry (IHC) is the most frequently used, convenient and cost-effective initial test for HER2 protein expression. HER2 IHC results are generally divided to four scale scores (range, 0 to 3+), depending on the percentage of positive tumor cells and staining intensity. The US Food and Drug Administration (FDA) recommends that HER2 IHC scores of 0 and 1+ must be considered as HER2 negative and those with HER2 (3+) scores should be regarded as HER2 positive while HER2 equivocal invasive breast cancer are those with HER2 (2+) score. This has to be further assessed by Fluorescent In Situ Hybridization (FISH), which is more accurate and reliable than IHC. However, the need for a skilled operator, long procedure, special equipment, and difficult preservation of slides for later review are the disadvantages (4) .
A fully automated method, Silver In Situ Hybridization (SISH) may overcome the disadvantages of FISH and it has the same accuracy of FISH. It is performed by counting black signals, which are dot-like on the conventional bright field light microscopy (5). "Advantages of SISH include high sensitivity for detection of single gene copies, quantifying DNA targets with high resolution, and tissue counterstaining with high contrast for visualizing the signal separately and determining tissue morphology" (6) .
The aim of the present work was to estimate HER2 gene status of infiltrative breast cancer cases with immunohistochemically equivocal (2+) score using the SISH technique and to investigate its association with some clinicopathological variables including age of patients, type of breast cancer, and ER and PR status.
Materials and Methods
Fifty-two formalin-fixed paraffin embedded tissue blocks from female patients with invasive breast carcinoma with score 2+ (equivocal) HER2 immunohistochemistry were collected during the period from September 2013 to October 2015. All cases were studied by Silver DNA In Situ Hybridization technique (SISH) in a private pathology laboratory to determine the HER2 gene amplification status; amplified versus nonamplified.
All cases were already studied by the immunohistochemistry technique in the same laboratory for ER and PR status; positive versus negative.
Correlation of HER2 gene status by the SISH technique was made with different parameters including: age of the patient, type of invasive mammary carcinoma, and ER and PR immunoreactivity.
Other clinicopathological information including tumor size, stage and lymph node status were not available, because the specimens included in the present work were incisional biopsies. All of the cases were moderately differentiated.
Immunohistochemistry
Immunoreactivity for all cases for HER2, ER, and PR was studied by the VENTANABenchMark-XT computerized automated system, using the ultraView Universal DAB Detection Kit. Four-micrometer-thickness tissue sections were used.
The antibodies used were: 1-HER2 rabbit monoclonal antibody (clone 4B5).
2-Estrogen receptor rabbit monoclonal antibody (clone SP1).
3-Progesterone receptor rabbit monoclonal antibody (clone 1E2).
The ultraView Universal DAB Detection Kit detects specific mouse and rabbit primary antibodies bound to an antigen in paraffin-embedded tissue sections. The specific antibody is located by a cocktail of enzyme labeled secondary antibodies (HRP Multimer). The complex is then visualized with hydrogen peroxide substrate and 3, 3'-diaminobenzidine tetrahydrochloride (DAB) chromogen, which produces a brown precipitate that is readily observed by light microscopy. The principal steps of the procedure is illustrated in Figure 1 .
The staining protocols followed for all three immuno-stains (HER2, ER, and PR) were in accordance with standard staining protocols of VENTANABenchMark-XT computerized automated system for each antibody. The immunohistochemistry results and scores were recorded independently by two pathologists, followed by a common review for agreement.
The immunoreactivity criterion for inclusion of all the cases in the study (HER2 score 2+, equivocal) was weak-moderate complete circumferential membranous staining in >10% of invasive cancerous cells. The staining protocols followed for all three immuno-stains (HER2, ER, and PR) were in accordance with standard staining protocols of VENTANABenchMark-XT computerized automated system for each antibody. The immunohistochemistry results and scores were recorded independently by two pathologists, followed by a common review for agreement.
The immunoreactivity criterion for inclusion of all the cases in the study (HER2 score 2+, equivocal) was weak-moderate complete circumferential membranous staining in >10% of invasive cancerous cells.
The immunoreactivity criteria for evaluation of all the cases in the study for ER and PR were in harmony with Allred method. Allred scoring system is a combination of proportion score and intensity The Allred final score value will fall in a range of 0 to 8; score of 0 to 2 was considered a negative result, and score of 3 to 8 was considered a positive result.
Silver DNA In Situ Hybridization (SISH)
Assessment of HER2 amplification using SISH procedure was studied by the VENTANABenchMark-XT computerized automated system; 4 µm thickness tissue sections were used. In brief, the procedure combines two basic detection kits, HER2 & chromosome 17 DNA probes cocktail, and other supplementary bulk solutions and reagents:
1-INFORM HER2 Dual ISH DNA Probe Cocktail: contains a cocktail of HER2 DNA probe and chromosome 17 DNA probe.
2-ultraView SISH DNP (dinitrophenyl) Detection
Kit: detects the HER2 DNA probe sequence. During the staining process, the DNP and DIG labeled probes are co-hybridized to their respective specific target DNA sequences (HER2 and chromosome 17, respectively) within the cell nuclei. Then detection of HER2 signals occurs first by ultraView SISH DNP Detection Kit, as a black intranuclear signal, followed by detection of chromosome 17 signals by ultraView Red ISH DIG Detection Kit, as a red intranuclear signal.
The staining protocol was in accordance with standard dual ISH staining protocol of VENTANABenchMark-XT computerized automated system, the procedure roughly takes 13 hours to complete, it is briefly summarized in Table 1 .
The slides were independently reviewed by two pathologists, followed by a common review for agreement. The HER2 black signals and chromosome 17 red signals were enumerated in tumor invasive cells nuclei, according to VENTANA HER2 SISH interpretation algorithm, and results were reported as a function of (HER2/chromosome 17) signals ratio to determine HER2 amplification status: HER2/chr17 ratio of ≥2.0 was considered amplified, while a ratio of <2.0 was considered non-amplified.
Statistical analysis
The statistical analysis of this study was performed using SPSS 21.0 (Chicago, IL, USA) and Microsoft Excel 2013. Categorical data were formulated as counts and percentages. Chi-square and Fisher exact tests were used to describe the association of these data. The lower level of accepted statistical significant difference was below or equal to 0.05. 
Results

Clinicopathological parameters
The study included 52 female patients with invasive breast carcinomas. Their ages ranged from 31 to 81 years with 25 cases (48.1%) younger than 50 years and 27 cases (51.9%) aged 50 or older (Table 2) .
Concerning the types of invasive breast carcinoma that are included in the present work; the majority of cases (44 out of 52) were of invasive Ductal Carcinoma Not Otherwise Specified (IDC-NOS), comprising 84.6%. The remaining cases were: Invasive Lobular Carcinoma (ILC) (2 cases, 3.8%), mixed IDC-NOS and ILC (2 cases, 3.8%), medullary carcinoma (2 cases, 3.8%), ILC pleomorphic type (1 case, 1.9%) and invasive mucinous carcinoma (1 case, 1.9%) ( Table 2) .
Immunohistochemical study of the cases revealed that half of the cases were ER positive (26 cases, 50%) ( Figure 4 ) and the other half showed negative ER status, while cases with positive PR status were 27 (51.9%), and other cases showed negative PR immunoreactivity (25 case, 48.1%) ( Table 2) . According to age, HER2 gene status showed non-significant difference in age groups between cases with amplified and non-amplified gene status (P=0.173) ( Table 3 ).
The comparison of HER2 gene amplification according to hormone status revealed a significant negative association between positive ER and PR status and HER2 gene amplification by SISH in the studied cases (P= 0.002 and 0.017, respectively) (Table 4) , however, the gene amplification status was not significantly different among types of invasive breast carcinoma (P=0.206) ( Table 5 ).
Discussion
Precise evaluation of HER2 status is vital to optimize the outcome of patients with mammary carcinoma (7).
Immunohistochemistry is sufficient for the initial HER2 assessment, but patients with tumors scored less than 3+ (particularly those interpreted as 2+) would benefit from FISH to assess HER2 status more precisely and to avoid erroneous prognostication and inappropriate management (8). Furthermore, FISH is a practically objective and quantitative method in detecting HER2 gene amplification on the nuclei of tumor cells. The drawbacks of this procedure are its high costs (10 times that of IHC), complexity, the need for a fluorescence microscope, the temporary signal (it requires a special camera), and its inability to perceive and evaluate tumor histomorphology (9). Technologies for HER2 testing include Chromogenic In Situ Hybridization (CISH) and SISH (10 There was a converse association between the expression of ER, PR expression and HER2 amplification in both preclinical and clinical studies (19) (20) (21) (22) (23) . This inverse relationship has been connected with the fact that estrogen and its receptor are requisites to suppress HER-2/neu. ER and HER-2/neu signaling are inversely correlated throughout a transcriptional repression of HER-2/neu by estradiol binding to ER (24) .
Hormone receptors assessment can predict the effectiveness of hormonal therapy in mammary carcinomas (25) . HER2-positive tumors have a higher association with ER and PR negativity (1, 26, 27) . In positive ER cases, HER2 overexpression was indicated. Such cases have worse survival compared to those showing positive ER and negative HER2 tumors, signifying that HER2 status is a valuable interpreter of response to hormone therapy (28) . Expression of PR influences the possibility of HER2 amplification in cases with positive ER (21) . A study concluded that HER2 amplification/overexpression was associated with lower ER/PR levels (19) .
Recently, a few articles have been published regarding outstanding effectiveness of the HER2 SISH method (29, 30) . Concordance between FISH and SISH was 98.2% (31) .
Furthermore, FISH is considered a typical method for assessing of HER2 gene (32) . However, disadvantages of this method include sophisticated analysis, fast fading of fluorescence, and lengthy procedure (31) .
Substitute techniques have been attempted (33) . The CISH is a simple satisfactory method to recognize HER2 gene copies using steps similar to immunohistochemistry, ordinary light microscope and everlasting signal intensity (34, 35).
Nevertheless, it is manually operated and timeconsuming. Silver DNA in Situ Hybridization is automated and time efficient in addition to the use of ordinary light microscopy and permanent signal intensity (31) . Around 12 to 13 hours is required to complete the SISH test, a time that is roughly half that of FISH and CISH, which require an average of 24 hours.
Conclusion
More than half of breast carcinoma cases with equivocal HER2 immunoreactivity showed nonamplified gene status; this result is important to be taken into consideration by oncologists during their management planning of patients with breast cancer. Amplified HER2 gene is significantly associated with negative ER and PR status that affects patients' management protocols and future outcome of the disease.
